Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M. Jackson, Pooja Dewan, Inder S. Anand, et al.
Circulation (2020) Vol. 142, Iss. 11, pp. 1040-1054
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8910
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1537
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 326-336
Open Access | Times Cited: 329
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer, Javed Butler, Faı̈ez Zannad, et al.
Circulation (2021) Vol. 144, Iss. 16, pp. 1284-1294
Open Access | Times Cited: 290
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Michael McDonald, Sean Virani, Michael Chan, et al.
Canadian Journal of Cardiology (2021) Vol. 37, Iss. 4, pp. 531-546
Open Access | Times Cited: 242
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 11, pp. 1381-1392
Open Access | Times Cited: 136
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 115
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
Revista Española de Cardiología (2022) Vol. 75, Iss. 6, pp. 523.e1-523.e114
Closed Access | Times Cited: 90
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt, et al.
Kidney International (2023) Vol. 104, Iss. 4, pp. 655-680
Open Access | Times Cited: 72
Chronic Kidney Disease as a Comorbidity in Heart Failure
Magdalena Szlagor, Jill Dybiec, Ewelina Młynarska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2988-2988
Open Access | Times Cited: 54
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 49
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah, Kavita Sharma, Barry A. Borlaug, et al.
European Heart Journal (2024) Vol. 45, Iss. 35, pp. 3254-3269
Open Access | Times Cited: 34
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety
Frederick Lang, Sergio Teruya, Ariel Weinsaft, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 4, pp. 938-947
Closed Access | Times Cited: 20
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Eva M. Boorsma, Joost C. Beusekamp, Jozine M. ter Maaten, et al.
European Journal of Heart Failure (2020) Vol. 23, Iss. 1, pp. 68-78
Open Access | Times Cited: 120
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Li Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
JACC Heart Failure (2021) Vol. 9, Iss. 4, pp. 254-264
Open Access | Times Cited: 104
Effect of dapagliflozin on anaemia in DAPA‐HF
Kieran F. Docherty, James P. Curtain, Inder S. Anand, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 4, pp. 617-628
Open Access | Times Cited: 74
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 59
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
G.B. John Mancini, Eileen O’Meara, Shelley Zieroth, et al.
Canadian Journal of Cardiology (2022) Vol. 38, Iss. 8, pp. 1153-1167
Open Access | Times Cited: 44
Practical outpatient management of worsening chronic heart failure
Nicolas Girerd, Nathan Mewton, Jean‐Michel Tartière, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 5, pp. 750-761
Open Access | Times Cited: 43
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction
Javed Butler, Muhammad Usman, Gerasimos Filippatos, et al.
JAMA Cardiology (2023) Vol. 8, Iss. 7, pp. 640-640
Open Access | Times Cited: 40
How to Manage Heart Failure With Preserved Ejection Fraction
Akshay S. Desai, Carolyn S.P. Lam, John J.V. McMurray, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 6, pp. 619-636
Closed Access | Times Cited: 38
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5027-5035
Open Access | Times Cited: 36
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
European Heart Journal (2023) Vol. 44, Iss. 31, pp. 2930-2943
Open Access | Times Cited: 36
Enhanced Decongestive Therapy in Patients With Acute Heart Failure
Gad Cotter, Beth A. Davison, Ovidiu Chioncel
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 13, pp. 1243-1252
Closed Access | Times Cited: 14
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial
Justin A. Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 3, pp. 628-637
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top